Zoster vaccine live for the prevention of shingles in the elderly patient

Jamie Zussman, Lorraine YoungDepartment of Medicine, Dermatology Division, David Geffen School of Medicine at the University of California, Los Angeles, CaliforniaAbstract: Shingles, also known as herpes zoster, is a common disease in the elderly population that is caused by reactivation of latent v...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jamie Zussman, Lorraine Young
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/4e1d402d982943a6bf383aed21437f3e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e1d402d982943a6bf383aed21437f3e
record_format	dspace
spelling	oai:doaj.org-article:4e1d402d982943a6bf383aed21437f3e2021-12-02T01:22:16ZZoster vaccine live for the prevention of shingles in the elderly patient1178-1998https://doaj.org/article/4e1d402d982943a6bf383aed21437f3e2008-06-01T00:00:00Zhttps://www.dovepress.com/zoster-vaccine-live-for-the-prevention-of-shingles-in-the-elderly-pati-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Jamie Zussman, Lorraine YoungDepartment of Medicine, Dermatology Division, David Geffen School of Medicine at the University of California, Los Angeles, CaliforniaAbstract: Shingles, also known as herpes zoster, is a common disease in the elderly population that is caused by reactivation of latent varicella zoster virus. Its manifestations and complications can lead to significant short- and long-term morbidity. In 2006, the United States Food and Drug Administration approved Zoster Vaccine Live (Zostavax®) for the prevention of herpes zoster in immunocompetent adults age 60 and over. The approval was based on the results of a large, multi-center clinical trial, the Shingles Prevention Study. This study showed that vaccination significantly decreased shingles incidence, burden of illness due to disease, and the development of, and severity of postherpetic neuralgia. This review offers an overview of varicella zoster virus infection and complications, a summary of the Shingles Prevention Study, and a critical analysis designed to aid the practicing physician who has questions about vaccine administration.Keywords: zoster vaccine, shingles, herpes zoster, postherpetic neuralgia, zostavaxJamie ZussmanLorraine YoungDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 241-250 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Jamie Zussman Lorraine Young Zoster vaccine live for the prevention of shingles in the elderly patient
description	Jamie Zussman, Lorraine YoungDepartment of Medicine, Dermatology Division, David Geffen School of Medicine at the University of California, Los Angeles, CaliforniaAbstract: Shingles, also known as herpes zoster, is a common disease in the elderly population that is caused by reactivation of latent varicella zoster virus. Its manifestations and complications can lead to significant short- and long-term morbidity. In 2006, the United States Food and Drug Administration approved Zoster Vaccine Live (Zostavax®) for the prevention of herpes zoster in immunocompetent adults age 60 and over. The approval was based on the results of a large, multi-center clinical trial, the Shingles Prevention Study. This study showed that vaccination significantly decreased shingles incidence, burden of illness due to disease, and the development of, and severity of postherpetic neuralgia. This review offers an overview of varicella zoster virus infection and complications, a summary of the Shingles Prevention Study, and a critical analysis designed to aid the practicing physician who has questions about vaccine administration.Keywords: zoster vaccine, shingles, herpes zoster, postherpetic neuralgia, zostavax
format	article
author	Jamie Zussman Lorraine Young
author_facet	Jamie Zussman Lorraine Young
author_sort	Jamie Zussman
title	Zoster vaccine live for the prevention of shingles in the elderly patient
title_short	Zoster vaccine live for the prevention of shingles in the elderly patient
title_full	Zoster vaccine live for the prevention of shingles in the elderly patient
title_fullStr	Zoster vaccine live for the prevention of shingles in the elderly patient
title_full_unstemmed	Zoster vaccine live for the prevention of shingles in the elderly patient
title_sort	zoster vaccine live for the prevention of shingles in the elderly patient
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/4e1d402d982943a6bf383aed21437f3e
work_keys_str_mv	AT jamiezussman zostervaccineliveforthepreventionofshinglesintheelderlypatient AT lorraineyoung zostervaccineliveforthepreventionofshinglesintheelderlypatient
_version_	1718403138536341504

Zoster vaccine live for the prevention of shingles in the elderly patient

Ejemplares similares